Jubilant Pharma Singapore Announces Sale of 25.8% Stake in Sofie Biosciences and Subsequent Merger, with Potential $139.4 Million Proceeds

Posted on 28/01/202408/02/2024 by bigbreakingwire

Jubilant Pharma Singapore is set to sell its entire 25.8% stake in Sofie Biosciences, with the anticipated proceeds reaching up to $139.4 million.

Sofie Biosciences is scheduled to merge with Trilantic North America by June 30.

If the merger transaction falls through, Jubilant Pharma Singapore is poised to receive termination-related fees of up to $7 million from Sofie.

bigbreakingwire

Stay informed with our financial updates, stocks, bonds, commodities. Get global & political insights. Follow us & enable notifications for the latest updates.

bigbreakingwire.in

Federal Reserve Chairman Powell Voices Concerns on Unsustainable Fiscal Path as U.S. National Debt Surpasses $34 Trillion

bigbreakingwire
06/02/2024
0

• Federal Reserve Chairman Jerome Powell expressed concern in a recent interview, stating that the U.S. is on an unsustainable fiscal path. • Powell emphasized […]

India Inc. Poised for Improved Profit Margins and Credit Metrics in H2 FY2025, Driven by Rural Demand and Government Spending

bigbreakingwire
02/12/2024
0

India Inc.’s operating profit margin (OPM) is expected to improve in the second half of the current financial year, driven by stronger rural demand, increased […]

Polycab Shares Plunge 21%, Wiping Out Rs 15,500 Crore in Investor Wealth: FPIs Hit Hard Amid Income Tax Raid Fallout

bigbreakingwire
11/01/2024
0

• Foreign portfolio investors incurred a loss exceeding Rs 1,900 crore as Polycab shares dropped by 21% following an income tax raid. • The market […]